A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
← catalyst calendarNCT07470879 · readout in 1,481 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
24estimated
Sites
25
Countries
Canada, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-28 | actual | When the study began enrolling |
| Primary completion | 2030-09-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-08-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colitis, Ulcerative
Intervention
- Drug: Etrasimod — also filed as APD334
Primary outcome
what the primary-completion date above is the date OFNumber and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52
measured Week 52
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed